We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Nanoparticles Deliver Small RNAs to Treat Pancreatic Cancer

By LabMedica International staff writers
Posted on 06 Feb 2018
Print article
Image: A micrograph of pancreatic ductal adenocarcinoma (the most common type of pancreatic cancer) (Photo courtesy of Wikimedia Commons).
Image: A micrograph of pancreatic ductal adenocarcinoma (the most common type of pancreatic cancer) (Photo courtesy of Wikimedia Commons).
A team of Israeli cancer researchers used novel supramolecular nanocarriers to deliver a potent combination of microRNA and siRNA to attach and destroy pancreatic ductal adenocarcinoma (PDAC) tumors in a mouse model.
 
MicroRNAs (miRNAs) are a small noncoding family of 19- to 25-nucleotide RNAs that regulate gene expression by targeting messenger RNAs (mRNAs) in a sequence specific manner, inducing translational repression or mRNA degradation, depending on the degree of complementarity between miRNAs and their targets. Many miRNAs are conserved in sequence between distantly related organisms, suggesting that these molecules participate in essential processes. In fact, miRNAs have been shown to be involved in the regulation of gene expression during development, cell proliferation, apoptosis, glucose metabolism, stress resistance, and cancer.
 
Short interfering RNAs (siRNAs) have a well-defined structure: a short (usually 21 base pairs) double-stranded RNA (dsRNA) with phosphorylated 5' ends and hydroxylated 3' ends with two overhanging nucleotides. These small RNAs can bind to other specific messenger RNA (mRNA) molecules and either increase or decrease their activity, for example by preventing an mRNA from producing a protein. RNA interference has an important role in defending cells against parasitic nucleotide sequences – viruses and transposons – but also in directing development as well as gene expression in general.
 
Investigators at Tel Aviv University (Israel) conjugated in parallel ethylenediamine and alkylamine moieties to form positively charged amphiphilic nanocarriers. These cationic nanocarriers were designed to utilize electrostatic-based interactions to form polyplexes with the negatively charged oligonucleotide cargo. The nanocarriers would facilitate oligonucleotide delivery by improving their stability in the bloodstream and enabling accumulation of the polyplexes at the tumor site due to enhanced permeability and the retention effect.
 
Based findings gleaned from The Cancer Genome Atlas (TCGA), the investigators used two negatively charged small RNAs: miR-34a for miRNA replacement therapy and PLK1 (polo like kinase 1)-siRNA for oncogene silencing in a PDAC mouse model.
 
They reported in the January 2, 2018, online edition of the journal Nature Communications that systemic administration of the RNA polyplexes to PDAC-bearing mice showed no toxicity and accumulated at the tumor, resulting in an enhanced antitumor effect due to inhibition of the MYC oncogene, a common target of both miR-34a and PLK1.
 
"Though 75% of pancreatic cancer patients die within 12 months of diagnosis, about 7% survive more than five years," said senior author Dr. Ronit Satchi-Fainaro, professor of physiology and pharmacology at Tel Aviv University. "We thought that if we could understand how some people live several years with this most aggressive disease, we might be able to develop a new therapeutic strategy. This treatment takes into account the entire genomic pattern, and shows that affecting a single gene is not enough for the treatment of pancreatic cancer or any cancer type in general."
 
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.